Argan vs Legence
AGX and LGN side by side, both in construction special trade contractors. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGX and LGN compare
Argan and Legence are about the same size, with market caps of $4.3B and $3.8B.
Legence grew revenue faster over the last twelve months (84.2% versus 29.0% for Argan).
Argan keeps more of each dollar of sales as profit, with a net margin of 15.1% compared with 1.0% at Legence.
Argan pays a dividend yielding 0.49%; Legence does not pay one.
Argan scores higher on the StockData Score (21 against 6 for Legence), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGX | LGN |
|---|---|---|
| Size and price | ||
| Market cap | $4.3B | $3.8B |
| Share price | $306.48 | $35.00 |
| Change, 1 year | −16.0% | −4.6% |
| Change, 5 years | 627% | – |
| Beta (5Y) | 0.82 | 2.77 |
| Employees | 1,409 | 7,000 |
| StockData Score | ||
| Total score | 21 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 5 (better) | 2 |
| Performance score | 6 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 24.2× | – |
| P/S | 3.6× | 0.9× (better) |
| P/B | 8.5× | 5.5× (better) |
| EV/EBITDA | 20.6× | 16.4× (better) |
| P/FCF | 7.9× (better) | 12.7× |
| PEG | 0.40 | – |
| FCF yield | 12.7% (better) | 7.9% |
| Fair value | $254.16 | $19.81 |
| Margin of safety | −20.6% (better) | −76.7% |
| Growth | ||
| Revenue growth (TTM) | 29.0% | 84.2% (better) |
| Revenue growth, 5Y average | 19.2% | – |
| Net income growth (TTM) | 53.0% | – |
| EPS growth (TTM) | 51.9% | – |
| EPS growth, 5Y average | 45.2% | – |
| Profitability | ||
| Gross margin | 20.9% (better) | 19.1% |
| Operating margin | 15.4% (better) | 3.7% |
| Net margin | 15.1% (better) | 1.0% |
| FCF margin | 45.9% (better) | 6.9% |
| Return on equity | 39.8% (better) | 8.4% |
| Return on invested capital | 396% (better) | 9.3% |
| Financial health | ||
| Debt / equity | 0.00 | 1.51 (better) |
| Net debt / EBITDA | – | 2.32 |
| Interest coverage | – | 2.5× |
| Current ratio | 1.50 (better) | 1.44 |
| Altman Z-score | 5.03 (better) | 2.18 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.49% | – |
| Payout ratio | 15.6% | – |
| Years of dividend growth | 4 | – |
| Dividend growth, 5Y average | 47.6% | – |
| Buyback yield | 0.29% | – |
| Shareholder yield | 0.78% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 99.4% | 79.0% |
| Held by insiders | 9.3% | 47.1% |
| Insider net buying, 12 months | −$147M (better) | −$2.5B |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 7.0% | 4.5% |
Go deeper
- AGX stock overview
- AGX income statement
- AGX valuation and score
- LGN stock overview
- LGN income statement
- LGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.